This study was designed to investigate the levels of expression of steroidogenic factor 1 (SF-1) and steroidogenic acute regulatory protein (StAR) in endometriosis, and to explore the association between these two factors and the menstrual cycle and the severity of endometriosis. Levels of SF-1 and StAR protein were evaluated using immunohistochemistry in 38 cases of endometriosis with ectopic endometria and in 25 normal endometria (controls). The SF-1 and StAR protein levels were significantly higher in ectopic endometria than in normal endometria. There was a significant correlation between the level of SF-1 and StAR in ectopic endometriotic tissues. It is concluded that protein levels of SF-1 and StAR are upregulated in ectopic endometria and are significantly correlated with the severity of endometriosis.
Introduction
Endometriosis is a condition in which active endometrial cells are deposited in areas outside the uterine cavity and occurs in about 10% of woman of reproductive age. 1 The main symptoms of endometriosis are dysmenorrhoea, chronic pelvic pain and infertility, affecting the health and life quality of women of reproductive years. 2 The molecular mechanisms that cause endometriosis are unclear: besides the possible immunological, environmental and genetic effects, it has been widely proven that ectopic endometrial cells have higher female hormone production and lower hormone inactivation activity compared with normal endometrial cells. 3 Several studies, however, have examined the mechanism that causes localized synthesis of female hormones and the function of this mechanism in endometriosis. 4 Some reports have shown that steroidogenic factor 1 protein (SF-1) and steroidogenic acute regulatory protein (StAR) play an important role in the synthesis of female hormones in ectopic endometrial cells. 3 The present study used immunohistochemical analysis to evaluate the expression levels of SF-1 and StAR in the ectopic endometrium from women with endo -Y Tian, B Kong, W Zhu et al.
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metriosis compared with normal endometrium. The relationship between the levels of SF-1 and StAR protein and different stages of endometriosis as well as the potential function of these proteins in the formation and development of endometriosis, was also investigated.
Patients and methods

PATIENTS, SAMPLE COLLECTION AND CLASSIFICATION
In this observational study ectopic human endometria were obtained from patients with ovarian or peritoneal endometriosis who underwent surgery at the Provincial Hospital affiliated to Shandong University, Jinan, Shandong, China, from September 2007 to October 2008. All patients were pathologically confirmed as having endometriosis and were classified according the classification system of the American Society of Reproductive Medicine (ASRM) 5 as having mild (stages I -II) or severe (stages III -IV) endometriosis. None of the endometriosis patients included in the study had received hormone treatment or antiendometriosis drug therapy for at least 3 months before the surgery. As controls, cases of pathologically normal endometria (proliferative and secretory phases) were obtained from diagnostic curettage or hysteroscopy during the same period of time. All patients who participated in the study provided written informed consent.
METHODOLOGY
Ovarian or peritoneal endometriotic cysts and control normal endometria were fixed using 10% paraformaldehyde before being paraffin embedded. Serial sections of 5 µm were prepared using an RM 2135 microtome (Leica Microsystems, Wetzlar, Germany) and stained with haematoxylin and eosin. Typical endometrial tissue sections, from both the endometriosis cases and normal endometrial controls, were selected and examined under a light microscope.
Indirect immunohistochemistry was used to evaluate levels of SF-1 and StAR protein. Tissue sections were prepared by microwaveheating in 10× citrate buffer, pH 6.0, for 10 min from the beginning of boiling and then rinsing three times in 20 mM phosphate buffered saline (PBS), pH 7.2, for 10 min each, before incubation with 1:200 dilutions of polyclonal anti-human SF-1 and StAR antibodies (PA1-560 and PA1-17176; ABR-Affinity BioReagents, Golden, CO, USA) at 37°C for 60 min. Tissue sections were then washed three times in 20 mM PBS, pH 7.2, for 2 min each, before incubation with a 1:1000 dilution of secondary mouseantirabbit antibody (Zhongshan Golden Bridge Biotechnology Co. Ltd, Bejing, China) at 37°C for 30 min. Indirect PV immunohistochemistry kits (PV6001 and PV6002;
Zhongshan Goldenbridge Biotechnology Co. Ltd) and a 3,3'diaminobenzidine chromogenic kit (Zhongshan Goldenbridge Biotechnology Co. Ltd) were used according to the manufacturer's instructions to visualize SF-1 and StAR. A tissue specimen known to express SF-1 and StAR was used as a positive control and 20 mM PBS was used in place of the primary antibody as a negative control.
DATA ANALYSIS
A pathological image analysis system (Image-Pro ® Plus version 4.5; Media Cybernetics Inc., Silver Spring, MD, USA) was used to carry out mean optical density 
STATISTICAL ANALYSIS
All data were expressed as mean ± SE. Statistical analysis was performed by Welch's t-test, analysis of variance and rank correlation analysis using SPSS ® version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value of < 0.05 was considered to be statistically significant.
Results
In total, ectopic human endometria were collected from 38 patients who had undergone surgery for ovarian or peritoneal endometriosis. Using the ASRM classification system, 5 24 cases had mild endometriosis (stages I -II) and 14 cases had severe endometriosis (stages III -IV). As controls, 25 cases of pathologically normal endometria (including both proliferative and secretory phases) were included in the study. The endometriosis patients were 23 -34 years old (29.5 ± 5.19 years) and the controls were 25 -36 years old (31.8 ± 5.47 years). There was no significant difference in age between the normal and endometriosis patients.
The SF-1 protein was shown to be expressed in the cytoplasmic and perinuclear regions of almost all endometriotic glandular cells with the exception of some stromal cells which demonstrated low SF-1 levels (Fig. 1A, 1B ). Most normal endometrial cells did not express SF-1, with the exception of a few cells that showed low SF-1 protein levels (Fig. 1C) . The level of SF-1 protein in endometriotic cells was statistically significantly higher than in normal endometrium (P < 0.05; Table 1 ). The StAR protein was detected in the cytoplasm of the majority of endometriotic glandular cells, but not in most stromal or other cell types ( Fig. 2A, 2B ). Most normal endometrial cells did not express StAR protein (Fig. 2C) . The level of StAR protein in endometriotic cells was statistically significantly higher than in normal endometrium (P < 0.05; Table 1 ). There were no significant differences between the levels of SF-1 or StAR protein in endometriosis patients in either the proliferative or secretory phase ( Table 1) .
In endometriotic tissues, StAR protein was primarily expressed in the same glandular cells that expressed SF-1. Rank correlation analysis showed a significant correlation between the levels of SF-1 and StAR protein in endometriotic cells of endometriosis patients (r = 0.726, P < 0.01) and levels of SF-1 and StAR in endometriotic cells were significantly related to progression of endometriosis: SF-1 and StAR protein levels were significantly higher in patients in the early stages compared with those in the advanced stages of endometriosis (P < 0.05; Table 2 ).
Discussion
Many studies have shown that endometriosis is oestrogen-dependent. 6 Aromatase is believed to be the key enzyme in oestrogen biosynthesis and to play an important role in the development of endometriosis. 7 Studies have also shown that prostaglandin E 2 (PGE 2 ) has a strong stimulatory effect on aromatase expression, increasing aromatase synthesis through the upregulation of cyclic adenosine monophosphate (cAMP) and a series of downstream signalling pathways in endometriosis-derived stromal cells. 8 Neither cAMP nor PGE 2 , however, increase aromatase expression in normal endometrial stromal cells. 9 Thus, an unknown aromatase regulator might play a key role in the development of ectopic endometria and the subsequent increase in oestrogen levels.
The SF-1 protein (also known as Ad4BP or 
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NR5A1) belongs to the nuclear receptor family of intracellular transcription factors. 10 A key regulator of steroid hormone receptors, SF-1 was originally found in the adrenal gland, gonads and other organs, and plays an important role in embryonic development and sexual differentiation. 10 It is also involved in the multi-level regulation of gene expression of many steroid hormonesynthesizing enzymes. 11 -14 Zeitoun et al. 15 suggested that SF-1 is the key regulator of aromatase transcription. 
Upregulation of SF-1 is induced by PGE 2 through cAMP and PGE 2 binds to the aromatase promoter II, resulting in the stimulation of aromatase expression. At the same time, SF-1 can also increase aromatase expression by inducing other transcription factors of the aromatase promoter II, including CCAAT/enhancer-binding proteinα, unidentified enhancers and co-activators 1 and 2. 15 Attar and Bulun 3 proposed a model for aromatase regulation in normal and ectopic endometrium by both SF-1 and chicken ovalbumin upstream promoter transcription factor II (COUP-TF II). According to this model, in normal endometrial stromal cells where there is no SF-1 expression, COUP-TF binds to the nuclear receptor, together with other 
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repressive transcription factors such as Wilm's tumour gene 1 (WT-1), and synergistically inhibits aromatase transcription. 3 Due to its higher binding affinity, in SF-1 expressing ectopic endometrial stromal cells, SF-1 out-competes COUP-TF for binding to the nuclear receptor, thereby stimulating aromatase expression. In agreement with this model, the present study demonstrated that SF-1 is expressed in ectopic but not in normal endometrial stromal cells.
As well as aromatase, StAR is another key enzyme involved in oestrogen synthesis. 3 It mediates cholesterol translocation from the cytoplasm to mitochondria and, thus, provides basic materials for oestrogen synthesis. 16, 17 There are, however, few studies on the regulation detailed mechanism of this cholesterol translocation. The present study demonstrated a correlation between the expression of SF-1 and StAR in ectopic endometrial stromal cells, consistent with data reported by Attar and Bulun. 3 The expression of SF-1 in ectopic endometrium might, therefore, mediate PGE 2 -and cAMPdependent mutual activation of multiple steroid-stimulating genes, including aromatase and StAR.
Ectopic expression of StAR and aromatase is the basis for oestrogen synthesis in ectopic endometrium. 3 In normal endometrial stromal cells, as there is no SF-1 expression, transcription factors such as COUP-TF and WT-1 can bind to related nuclear receptors, thereby inhibiting StAR and aromatase expression. 3 In contrast, SF-1 induces StAR and aromatase expression in ectopic endometrial stromal cells and stimulates oestrogen synthesis which, in turn, promotes cyclo-oxygenase-2 expression and upregulates PGE 2 . 3 Although SF-1 may play a pivotal role in this mechanism, as yet the regulation of SF-1 in endometriosis is not understood. Some studies have suggested that methylation of the SF-1 promoter and the upregulation of stimulatory factor-2 might play important roles in SF-1 regulation. 18, 19 To investigate the roles of SF-1 and StAR in endometriosis, any association between the expression levels of these proteins and the menstrual cycle and stage of endometriosis was evaluated. The results showed that the expression levels of SF-1 and StAR in ectopic endometria were significantly correlated with the stage of endometriosis; higher expression of SF-1 and StAR were observed in the early stages compared with the advanced stages of endometriosis. This finding reflects results previously reported by Sun et al. 20 which suggested that the activation of SF-1 and StAR, as well as aromatase, might play important roles in the formation and early development of endometriosis. The present study did not, however, show any significant difference between the expression of SF-1 and StAR in the proliferative or secretory phases. Thus, further studies are needed to address the relationship between the expression SF-1 and StAR, and the menstrual cycle.
In summary, the present study showed that protein levels of SF-1 and StAR are upregulated in ectopic endometria and are significantly correlated with the severity of endometriosis, hence appear to play important roles in the formation and development of endometriosis. The regulation of SF-1 and StAR and their relationship with aromatase, COUP-TF, WT-1 and other transcription factors need to be further investigated.
